ClinicalTrials.gg

Program

mocertatug rezetecan

Also written as “Mocertatug rezetecan”, “HS-20089” and “Mocertatug rezetecan (Mo-Rez)”.

In GlaxoSmithKline’s pipeline, ADC targeting B7-H4. Its studies are mostly in Ovarian Neoplasms · Endometrial Neoplasms · Neoplasms, led by 2 companies.

Furthest: phase 3, since Dec 12, 202511 company-led studies, 11 open or runningLicense: Hansoh → GSK, Oct 2023Next primary completion: Mar 7, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline66 open or runningphase 3since Dec 12, 2025May 21, 2024Sep 22, 2027phase 1 · NCT06431594
Hansoh Pharmaceutical Group55 open or runningphase 3since Feb 25, 2025Oct 29, 2021Mar 7, 2027phase 3 · NCT06855069
  • Named in GlaxoSmithKline’s own pipeline as mocertatug rezetecan GSK5733584, phase 3, as of Sep 30, 2026 (source).
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20089 (B7-H4 ADC), phase 3, as of Aug 26, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseGSK licensed it from Hansoh, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Oct 20, 2023 · Source: GSK, Oct 20, 2023

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2021First study: phase 1 study in Advanced Solid TumorNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT05263479 · 177 planned · China
  2. Aug 16, 2023Phase 2 study in Ovarian NeoplasmsHansoh Pharmaceutical Group · NCT06014190 · 460 planned · China
  3. Oct 20, 2023GSK licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · GSK
  4. May 21, 2024GlaxoSmithKline’s first study: phase 1 study in NeoplasmsNew to GlaxoSmithKlineGlaxoSmithKline · NCT06431594 · 675 planned · United States, Argentina, Australia and more
  5. Jan 7, 2025Phase 1 study in Ovarian NeoplasmsHansoh Pharmaceutical Group · NCT06769425 · 157 planned · China
  6. Feb 25, 2025Phase 3 study in Ovarian NeoplasmsHansoh Pharmaceutical Group · NCT06855069 · 468 planned · China
  7. Dec 12, 20252 phase 3 studiesPhase 3 reachedGlaxoSmithKline · NCT07286331, NCT07286266
  8. Jun 29, 20262 phase 3 studiesGlaxoSmithKline · NCT07684612, NCT07684599
  9. Jul 1, 2026Phase 3 study in Ovarian NeoplasmsGlaxoSmithKline · NCT07694427 · 720 planned · Argentina, Australia, Canada and more
  10. Sep 2, 2026Phase 3 study in Platinum-sensitive Recurrent Ovarian CancerHansoh Pharmaceutical Group · NCT07821606 · 460 planned · China
  11. Oct 15, 2026Primary completion moved from 2029-12-17 to 2030-07-22Date moved laterphase 3 · +7 months · NCT07286266

Ahead

  1. Mar 7, 2027Primary completion: phase 3 study in Ovarian NeoplasmsHansoh Pharmaceutical Group · NCT06855069
  2. Sep 22, 2027Primary completion: phase 1 study in NeoplasmsGlaxoSmithKline · NCT06431594
  3. Feb 29, 2028Primary completion: phase 3 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07286331
  4. Jul 23, 2029Primary completion: phase 3 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07684599

TargetBeta

“ADC targeting B7-H4”the company's pipeline, read by Claude · source
“B7-H4 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of mocertatug, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule

Other programs on VTCN1

ProgramCompanyFurthest phaseStudies
Anti-B7-H4 Antibody Drug Conjugate BG-C9074ruleBeOne Medicinesphase 32
puxitatug samrotecanAstraZenecaphase 32
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleabl-bio-incphase 22
Anti-B7-H4/MMAE ADC LNCB74ruleligachem-biosciences-incphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07821606Platinum-sensitive Recurrent Ovarian Cancer · China3Not yet recruitingHansoh Pharmaceutical GroupDec 30, 2029460
NCT07694427Ovarian Neoplasms · Argentina, Australia, Canada and more3RecruitingGlaxoSmithKlineSep 6, 2029720
NCT07684612Ovarian Neoplasms · Australia, Canada, Japan and more3RecruitingGlaxoSmithKlineMay 21, 2030690
NCT07684599Endometrial Neoplasms · Canada, Japan, South Korea3RecruitingGlaxoSmithKlineJul 23, 2029610
NCT07286331Endometrial Neoplasms · United States, Argentina, Australia and more3RecruitingGlaxoSmithKlineFeb 29, 2028600
NCT07286266Ovarian Neoplasms · Australia, Canada, Japan and more3RecruitingGlaxoSmithKlineJul 22, 2030450
NCT06855069Ovarian Neoplasms · China3RecruitingHansoh Pharmaceutical GroupMar 7, 2027468
NCT06769425Ovarian Neoplasms · China1RecruitingHansoh Pharmaceutical GroupMay 7, 2026157
NCT06431594Neoplasms · United States, Argentina, Australia and more1RecruitingGlaxoSmithKlineSep 22, 2027675
NCT06014190Ovarian Neoplasms · China2RecruitingHansoh Pharmaceutical GroupDec 31, 2025460
NCT05263479Advanced Solid Tumor · China1RecruitingHansoh Pharmaceutical GroupDec 31, 2024177

How it is read

Names in the registry

  • “Mocertatug rezetecan”, 5 entries
  • “HS-20089”, 2 entries
  • “Mocertatug rezetecan (Mo-Rez)”, 1 entry
  • “HS-20089+Bevacizumab”, 1 entry
  • “HS-10502 + HS-20089”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.